PIN: 172641 Mahdi Najafzadeh

1. Most significant Contributions

N/A

2. Activities and Contributions

N/A

3. Interruptions and Delays

N/A

4. Patents and Intellectual Property Rights

N/A

5. Publications

Published Refereed Papers

1. Najafzadeh M, Marra CA, Galanis E, Patrick D. Cost-Effectiveness of a Universal Herpes

Zoster Vaccine Strategy. Pharmacoeconomics (Forthcoming), PEC-S-08-02527R1.
My contribution: reviewed literature, developed and ran the model, created the results, wrote the
manuscript (65%).

2. Lynd LD, Najafzadeh M, Colley L, Byrne M, Willan A, Sculpher MA, Johnson FR. Using the
incremental net-benefit framework for quantitative benefit-risk analysis in regulatory decision
making - a case study of alosetron in irritable bowel syndrome. Value Health, Sep 10, 2009.
Epub ahead of print.
My contribution: developed and ran the model, created the results, prepared the first version of
abstract (30%).

3. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Vandemheem KL, Sullivan S, Jones PW,
Fitzgerald MJ. Cost-Effectiveness of Therapy with Combinations of Long-Acting
Bronchodilators and Inhaled Steroids for Treatment of COPD: An Economic Evaluation of the
OPTIMAL Study. Thorax, July 2008.
My contribution: developed the model and ran the analysis, contributed in writing of the
manuscript (40%).

4. Najafzadeh M, Sadatsafavi M, Marra CA. Re: Evaluation of the cost-effectiveness in the United
States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine
26 (2008).
My contribution: Identified the issue, wrote the letter (75%).

5. Sadatsafavi M, Najafzadeh M, Marra CA, Lynd LD. (2008) Reliability Studies Are not Using
Enough Observers for Robust Estimation of Observer Agreement: A Simulation Study. Journal
of Clinical Epidemiology. 61(7):722-7.
My contribution: discussed the idea, reviewed and commented on the first version of manuscript
(25%).

13 October 2008
 PIN: 172641 Mahdi Najafzadeh
6. C.A. Marra, S.A. Marion, D.P. Guh, M. Najafzadeh, F. Wolfe, J.M. Esdaile, A.E. Clarke, M.A.
Gignac, A.H. Anis. Not All ‘‘Quality-Adjusted Life Years’’ Are Equal. Journal of Clinical
Epidemiology 2007; 60: 616-624.
My contribution: I corrected part of the model and method, re-ran the results and created new
graphs for the second revision of manuscript that was accepted as the final version (20%).

7. Sadatsafavi M, Najafzadeh M. Cost-optimization of Screening for Latent Tuberculosis in Close

Contacts. Eur Respir J. 2006; 28(6):1285.
My contribution: discussed the idea and commented on the first version (20%).

8. Sadatsafavi M, Najafzadeh M, Marra CA. (2008) Acceptability Curves Could Be Misleading

When Correlated Strategies Are Compared. Journal of Medical Decision Making. 28(3):306-7.
My contribution: discussed the idea and commented on the first version (20%).

Submitted Refereed Papers

9. Lynd LD, Marra CA, Najafzadeh M, Sadatsafavi M. A benefit-risk Analysis of Rofecoxib

Relative to Naproxen in Arthritis - An Application of the Incremental Net-Benefit Framework.
Provisionally accepted by Pharmacoepideiology and Drug Safety, Manuscript ID PDS-08-0164.
My contribution: reviewed literature, developed and ran the model, created the results,
participated in writing of the manuscript (30%).

Published Abstracts

10. Najafzadeh M; Marra CA; Lynd LD; Sadatsafavi M; Sin DD. The Economic Value of a
Potential Biomarker for Chronic Obstructive Pulmonary Disease. 31st Annual Meeting of the
Society for Medical Decision Making, October 18 - 21, 2009, LA, USA.
My contribution: participated in developing the model, creating the results, and wrote the first
version of abstract (40%).

11. Sadatsafavi M, Najafzadeh M. A Note on the Usage of Cost-effectiveness Acceptability Curves.

British Journal of Sport Medicine e-Letters. (Letter) 2006.
My contribution: Discussed existing problem, refined the idea, reviewed related publications and
final version of note (30%).

12. Najafzadeh M, Marra CA, Galanis E, Patrick D. The Cost-effectiveness of Herpes Zoster
Vaccine. INFORMS annual meeting November 4-7 2007, Seattle, Washington. Oral Presentation
on November 5 2007 in the “Operations Research in Medicine and Health Care” cluster.
My contribution: created the model and the results, wrote the first version of abstract (65%).

13. Lynd LD, Najafzadeh M, Colley L, Willan AR, Sculpher MJ. Quantitative risk-benefit analysis
of alosetron in irritable bowel syndrome: a patient-level meta-cohort analysis. 4th Canadian
Therapeutics Congress, May 27-30, 2007 Halifax, Nova Scotia.
My contribution: developed and ran the model, created the results, prepared the first version of
abstract (45%).

14. Marra CA, Sullivan SD, Najafzadeh M, Sadatsafavi M, Jones PW, Aaron S, FitzGerald JM.
Mapping the EQ-5D from The St. George Respiratory Questionnaire in a Clinical Trial of COPD

14 October 2008
 PIN: 172641 Mahdi Najafzadeh
th
Treatments- Results from The OPTIMAL Trial. ISPOR 10 Annual European Congress, 20-23
October, 2007, Dublin, Ireland.
My contribution: developed the model and created the results, wrote the first version of abstract
(50%).

15. Lynd LD, Marra CA, Najafzadeh M, Sadatsafavi M. Harm-benefit analysis of rofecoxib versus
naproxen for the treatment of rheumatoid arthritis patients: a discrete event simulation. Can J
Clin Pharmacol 2006; 13(1): e133.
My contribution: I developed and ran the model, created results, made graphs and tables and
wrote first version of manuscript (30%).

16. Larry D Lynd, Carlo A Marra, Mehdi Najafzadeh, Mohsen Sadatsafavi. Risk-Benefit Analysis
of Rofecoxib versus Naproxen for the Treatment of Rheumatoid Arthritis Patients: A Discrete
Event Simulation. 22nd International Consortium in Psychiatric Epidemiology (ICPE), Lisbon,
Portugal.
My contribution: I developed and ran the model, created results, made graphs and tables and
wrote first version of manuscript (30%).
17. Sadatsafavi M, Moayyeri A, Ganjizadeh S, Shalmani HT, Najafzadeh M. Impact of Observer
Variation on Post Test Probability, Results from a Simulation Study. Congress of Epidemiology
2006, June 21-24, 2006, Seattle, WA, USA (poster presentation, appeared in the American
Journal of Epidemiology, 163 (11) June 2006, suppl 2).

Research Reports

18. Marra CA, Najafzadeh M. Cost-effectiveness of Infliximab in the Treatment of Patients with
Moderate to Severe Ulcerative Colitis: An Analysis of the ACT1 and ACT2 Trials from a
Canadian Perspective. Research Report Submitted to Schering Canada, Quebec. August 2006.

19. Sadatsafavi M, Najafzadeh M, Davis J, Marra CA. Cost-Effectiveness Analysis of Four ‘Test
and Treat’ Strategies for Helicobacter pylori Among Patients with Dyspepsia. Research Report
submitted to British Columbia Center for Disease Control, Vancouver, BC. July 2007.

15 October 2008